An efficient route to novel 2-(Salicylmethylidine)imidazolidines and (Salicylmethylidene)hexahydropyrimidines through reactions of 2-(N-methylanilino)-3-formylchromone with aliphatic diamines

Synlett

Volumn , Issue 2, 2003, Pages 256-258

  Singh, Gurmit ^a   Singh, Gurpinder ^a   Ishar, M P S ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Chromones; Diamines; Hexahydropyrimidines; Imidazolidines; Nucleophilic substitution

Indexed keywords

(SALICYLMETHYLIDENE)HEXAHYDROPYRIMIDINE DERIVATIVE; 2 (N METHYLANILINO) 3 FORMYLCHROMONE; 2 (SALICYLMETHYLIDINE)IMIDAZOLIDINE DERIVATIVE; ALIPHATIC AMINE; CHROMONE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ANALYSIS;

EID: 0037284622     PISSN: 09365214     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36780     Document Type: Article

References (42)

1. (a) Silverman, R. B. In Organic Chemistry of Drug Design and Drug Action; Academic Press Inc.: San Diego, 1992, Chap. 2, 4-50.
2. (b) Comprehensive Medicinal Chemistry, Vol. 4; Hansch, C.; Sammes, P. G.; Taylor, J. B., Eds.; Pergamon Press: London, 1990.
3. (c) Musser, J. H. In Medicinal Chemistry for the 21st Century; Wermuth, C. G., Ed.; Blackwell Scientific Publications: Oxford, 1992, 25-38.
4. (d) Austel, V. In Modern Drug Research; Martin, Y. C.; Kutter, E.; Austel, V., Eds.; Marcell Dekker: New York, 1989, 243-307.
5. (e) Burger, A. In Burgers Medicinal Chemistry and Drug Discovery, 5th ed., Vol. 1; Wolf, M. E., Ed.; John Wiley and Sons: New York, 1996, Chap. 1, 3-8.
6. (a) Thompson, L. A.; Ellman, J. A. Chem. Rev. 1996, 96, 555.
7. (b) Fruchtel, J. S.; Jung, G. Angew. Chem., Int. Ed. Engl. 1996, 35, 17.
8. (c) Nezfi, A.; Ostresh, J. M.; Houghten, R. A. Chem. Rev. 1997, 97, 449.
9. (d) Robert, G. F. J. Comb. Chem. 2000, 2, 195.
10. (a) Comprehensive Medicinal Chemistry, Vol. 6.; Hansch, C.; Sammes, P. G.; Taylor, J. B., Eds.; Pergamon Press: London, 1990.
11. (b) Lednicer, D. Strategies for Organic Drug Synthesis and Design; John Wiley and Sons: New York, 1998, 185-241.
12. (c) Timmerman, P. B. M.; Smith, R. D. In Burgers Medicinal Chemistry and Drug Discovery, 5th ed., Vol. 2; Wolf, M. E., Ed.; John Wiley and Sons: New York, 1996, 265-321.
13. (d) Michael, M. C.; Schafers, R. J. Cardiovasc. Pharmacol. 1992, 29 (Suppl .4), S24.
14. (e) Safar, M. E. Am. J. Med. 1989, 87 (Suppl. 3C), 24S.
15. (f) Robinson, C. P. Drugs Today 1988, 24, 557.
16. (g) Timmerman, P. B. M.; Van Zwieten, P. A. Eur. J. Med. Chem. 1980, 15, 233.
17. (h) Houston, M. C. Prog. Cardiovasc. Dis. 1981, 23, 337.
18. (i) Stump, D. C.; Macfarlane, D. E. J. Lab. Clin. Biol. Res. 1983, 102, 779.
19. (j) U'Prichard, D. C. Prog. Clin. Biol. Res. 1981, 71, 53.
20. (k) Rout, B.; Leclerc, G. Bull. Soc. Chim. Fr. 1979, 520.
21. (l) Haron, D. W. G.; Shank, R. G. Lancet 1981, 1, 351.
22. (m) Haron, D. W. G.; Shank, R. G. Eur. Heart J. 1985, 6, 722.
23. (n) Heidenreich, O.; Fuelgraff, G.; Baumeister, L.; Schmiz, K. Arch. Expt. Pathol. Pharmakol. 1964, 249, 432.
24. (o) Heidenreich, O.; Baumeister, L.; Fuelgraff, G.; Keller, P.; Kook, Y. Arch. Int. Pharmadyn. 1965, 156, 348.
25. (p) Outt, P. E.; Ares, J. J.; Roberts, G. E.; Wang, X.; Cupps, T. L.; Wireko, F. C. J. Org. Chem. 1998, 63, 5762.
26. (q) Rosatti, G. F.; Polleto, M. G. Farmaco 1966, 21, 204.
27. (r) Campbell, W. R.; Polter, D. E. Prog. Neuro Psych. Biol. Psych. 1994, 18, 1051.
28. (s) Peckkhold, J. C. Curr. Ther. Res. 1980, 27, 111.
29. (a) Timmerman, P. B. M.; Van Zwieten, P. A. J. Med. Chem. 1977, 20, 1636.
30. (b) Timmerman, P. B. M.; Van Zwieten, P. A. Eur. J. Med. Chem. 1980, 15, 233.
31. (c) Velly, J. J. Pharmacol. 1977, 8, 351.
32. (d) Kamitani, T.; Kamamoto, M.; Truzioka, K.; Terai, T.; Minovu, O.; Ono, T.; Kikuchi, K.; Kumada, S. Jpn. J. Pharmacol. 1985, 39, 251.
33. (e) Biedermann, J.; Borbe, H.; Graf, E.; Hirlboll, G.; Prop, G. German Patent DE 3,407.509; Chem. Abstr., 1986, 104, 15084v.
34. Yu, Y.; Ostresh, J. M.; Houghten, R. A. J. Org. Chem. 2002, 67, 3138.
35. (a) Ishar, M. P. S.; Kumar, K.; Singh, R. Tetrahedron Lett. 1998, 39, 6547.
36. (b) Ishar, M. P. S.; Kumar, K. Tetrahedron Lett. 1999, 40, 175.
37. (c) Ishar, M. P. S.; Singh, G.; Kumar, K.; Singh, R. Tetrahedron 2000, 56, 7817.
38. (d) Singh, G.; Singh, R.; Girdhar, N. K.; Ishar, M. P. S. Tetrahedron 2002, 58, 2471.
39. (e) Singh, G.; Singh, L.; Ishar, M. P. S. Tetrahedron 2002, 58, in press.
40. General Procedure for Reactions of 2-(N-Methylanilino)-3-formylchromones (3a-c) with Aliphatic Diamines (Ethylenediamine and 1,3-Diaminopropane): 2-(N-Methylanilino)-3-formylchromones (3a-c. 1.0 mmol) were dissolved in acetonitrile-water (80:20, 50 mL) at reflux and the solutions of diamines (1.0 mmol) in acetonitrile (5 mL) were added to the above solutions. The contents were heated at reflux for 2 h, after which the solvent was evaporated under vacuum. The crude products were directly crystallized and recrystallized from acetone.
41. abstract
42. (b) Jackman, L. M.; Timothy, F. J. Am. Chem. Soc. 1975, 97, 2811.